FDA Approves Pembrolizumab for Esophageal or GEJ Carcinoma

On March 22, 2021, the U.S. Food and Drug Administration (FDA) approved pembrolizumab in combination with platinum- and fluoropyrimidine-based chemotherapy for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation.

Read the FDA announcement.

Read Merck's announcement.

Posted 3/23/2021